Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia
复制标题
DOI:
10.1128/aac.00939-06
复制
发表时间:
2007-07-01
影响因子:
4.9
通讯作者:
Schentag, Jerome J.
中科院分区:
文献类型:
--
作者:
Moise, Pamela A.;Sakoulas, George;Schentag, Jerome J.
We examined the relationship between the time to clearance of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia while patients were receiving vancomycin therapy and the in vitro bactericidal activity of vancomycin. Vancomycin killing assays were performed with 34 MRSA bloodstream isolates (17 accessory gene regulator group II [agr-II] and 17 non-agr-II isolates) from 34 different patients with MRSA bacteremia for whom clinical and microbiological outcomes data were available. Vancomycin doses were prospectively adjusted to achieve peak plasma concentrations of 28 to 32 mu g/ml and trough concentrations of 8 to 12 mu g/ml. Bactericidal assays were performed over 24 h with similar to 10(7) to 10(8) CFU/ml in broth containing 16 mu g/ml vancomycin. The median time to clearance of bacteremia was 6.5 days for patients with MRSA isolates demonstrating >= 2.5 reductions in logo CFU/ml at 24 h and > 10.5 days for patients with MRSA isolates demonstrating < 2.5 log(10) CFU/ml by 24 h (P = 0.025). The median time to clearance was significantly longer with MRSA isolates with vancomycin MICs of 2.0 mu g/ml compared to that with MRSA isolates with MICs of